Table 1.

Participating Trials

Refer- ence	Sample Size	QOL Scale	QOL Schedule	AE Criteria	AE Schedule
34	30	UNISCALE	BL, Q3 Weeks	CTC 2.0	Q3 Weeks
35	82	UNISCALE	BL, 3& 5 months post reg; 3 mo, 1 & 2 year post tx	CTC 2.0	Q28 days while on tx, then 2, 3, 6, 9, 12, 16, 20, 24, 30, 36, 48, and 60 months post tx
36	135	UNISCALE FACT-L	BL, at time of tumor measurement (anywhere from 28 days to 8 weeks)	CTC 2.0	Q28 days
*	106	UNISCALE LCCS	BL, Q28 days	CTC 2.0	Q28 days
37	11	UNISCALE	BL, cycle 2 (day 42), after chemo (day 132); 3 mo, 1 & 2 year post tx	CTC 2.0	Q21 days for 2 cycles, then Q48 days for one cycle, then Q21 days for 2 more cycles, then Q16 days for 1 cycle, then Q3 months for 1 year, Q4 months for 1 year, and Q6 months for 1 year
38	64	UNISCALE SDS	BL, prior to cycle 3 (day 64); 3 mo. and 1 year post tx	CTC 2.0	Q21 days
39	59	UNISCALE LCSS	BL and at 8 weeks after treatment initiation	CTC 2.0	Q28 days until end of treatment, then Q3 months for 1 year
40	56	FACT-L, FLIC	BL, end of RT (week 7–8); q 3 mo for 1 year; then annually	CTC 2.0	Weekly during RT, then 3, 6, 9, and 12 months after RT, then annually
41	134	BDI, TDI	BL; q 3 mo. For 1 yr post tx.	Coopera tive Group CTC	Weekly during RT (through day 90), then 3, 6, 9, and 12 months, then annually
*	8	LCSS	BL, weeks 8 & 1;, at 3, 6, 9, 12, 18 & 24 mos. Post tx	Coopera tive Group CTC	Q7 days for 8 weeks, then at 12 weeks, then at 3, 6, 9, 12, 18, and 24 months after RT
43	29	FACT-L TOI	BL, start of cycle 2- 6, and at week 22	CTC 2.0	Q21 days for 3 cycles, then Q28 days for 3 cycles, then week 22, then 3, 6, 9, 12, 18, 24, 36,42, and 48 months after treatment
43, 44	222	HRQOL	BL, then at weeks 13 and 25.	SWOG toxicity criteria	Q4 Weeks during treatment, then Q3 months thereafter

^*There is no published manuscript